Fely Tacataca Embrado, NPC

Fely Embrado practices at Loma Linda University Medical Center in Loma Linda, California, part of Seventh-day Adventist Church.

Fely Embrado's NPI, 1902417124, was assigned on August 11, 2020. Fely Embrado holds California license NP95015043.

Fely Embrado's primary practice is Loma Linda University Medical Center, at 11234 Anderson St, Loma Linda, CA 92354 in San Bernardino County. The practice phone is (909) 558-4000.

Fely Embrado's primary practice is Loma Linda University Medical Center in Loma Linda, California, part of Seventh-day Adventist Church. The medical group on file is Loma Linda University Faculty Medical Group (LLUFMG). Dmand AI also links Fely Embrado to 4 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Fely Embrado practices, 2 sites in all. Vendor and product names are available with a free account.

Nurse practitioner is Fely Embrado's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Fely Embrado is licensed in California.

Dmand AI lists lower back pain, muscle pain, fibromyalgia, and limb pain and underactive thyroid among the conditions Fely Embrado treats.

CMS data shows 316 Medicare services from Fely Embrado across 3 procedure codes in 2024, for 92 Medicare patients. Medicare paid $18,086 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 92 Medicare patients who saw Fely Embrado in 2024. The largest group is under 65, with 39 patients. 75% of them have chronic kidney disease, and 75% have diabetes. 72% are also on Medicaid. Their average risk score is 8.92, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Fely Embrado's median patient age at 62, with 45% women.

In 2024, Fely Embrado wrote 197 Medicare Part D claims for 57 patients. 97% of them were for generic drugs. CMS names the drug for 104 of them, across 6 drugs with 11 or more claims each, at $6,483 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Fely Embrado for performance year 2024, reported as part of a group. Fely Embrado accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 2 general payments to Fely Embrado from 2 drug and device companies in 2024. Food and beverage make up the largest share, 100% of the total. Ardelyx, Inc. paid the most, $125.

Dmand AI lists 1 award for Fely Embrado, most recently Summa Cum laude in 2020.